Steven LE GOUILL
Institut Curie · Lymphoma Study Association · INSTITUT CURIE - Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven LE GOUILL as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06558604 · Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaThe Lymphoma Academic Research Organisation · recruiting · Lymphoma, Mantle-Cell · study chair
- Ph3NCT06195709 · ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsInstitut Curie · recruiting · Breast Carcinoma · study director
- Ph1/Ph2NCT06067061 · "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerInstitut Curie · terminated · Triple Negative Breast Neoplasms · study director
- N/ANCT04804735 · Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally IVAD for Chemotherapy Under Local AnesthesiaInstitut Curie · completed · Implanted Venous Access Device · study director
- Ph2NCT04802590 · Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaThe Lymphoma Academic Research Organisation · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT04720729 · Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast CancerInstitut Curie · terminated · HER2-negative Metastatic Breast Cancer · study chair
- Ph1/Ph2NCT04446962 · LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Institut Curie · active not recruiting · Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary · study director
- N/ANCT04328298 · French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)The Lymphoma Academic Research Organisation · recruiting · Hematopathology Eligible or CAR-t Cell Treatment · principal investigator
- Ph1NCT02920697 · Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin LymphomaInstitut de Recherches Internationales Servier · completed · Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) · principal investigator
- Ph2NCT02896582 · Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven MaintenanceThe Lymphoma Academic Research Organisation · completed · Mantle Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02558816 · A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsNantes University Hospital · completed · Mantle Cell Lymphoma · principal investigator
- Ph3NCT01659099 · GA In NEwly Diagnosed Diffuse Large B Cell LymphomaThe Lymphoma Academic Research Organisation · terminated · Diffuse Large B Cell Lymphoma CD20 Positive · study chair
- Ph1/Ph2NCT01389427 · Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).The Lymphoma Academic Research Organisation · completed · Mantle Cell Lymphoma Refractory · principal investigator
- Ph3NCT00921414 · Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceFrench Innovative Leukemia Organisation · completed · Mantle Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:30 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.Future Oncol · 202125 citationsRCR 1.2
- Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.Lancet Haematol · 201822 citationsRCR 0.7
- Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.Ann Hematol · 202218 citationsRCR 1.4